138 related articles for article (PubMed ID: 27328945)
1. Validation of the CPS + EG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Abdelsattar JM; Al-Hilli Z; Hoskin TL; Heins CN; Boughey JC
Ann Surg Oncol; 2016 Oct; 23(10):3206-11. PubMed ID: 27328945
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Bergquist JR; Murphy BL; Storlie CB; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 Nov; 24(12):3510-3517. PubMed ID: 28828583
[TBL] [Abstract][Full Text] [Related]
3. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.
Mittendorf EA; Jeruss JS; Tucker SL; Kolli A; Newman LA; Gonzalez-Angulo AM; Buchholz TA; Sahin AA; Cormier JN; Buzdar AU; Hortobagyi GN; Hunt KK
J Clin Oncol; 2011 May; 29(15):1956-62. PubMed ID: 21482989
[TBL] [Abstract][Full Text] [Related]
4. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
Mittendorf EA; Vila J; Tucker SL; Chavez-MacGregor M; Smith BD; Symmans WF; Sahin AA; Hortobagyi GN; Hunt KK
JAMA Oncol; 2016 Jul; 2(7):929-36. PubMed ID: 26986538
[TBL] [Abstract][Full Text] [Related]
5. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer.
Vila J; Teshome M; Tucker SL; Woodward WA; Chavez-MacGregor M; Hunt KK; Mittendorf EA
Ann Surg; 2017 Mar; 265(3):574-580. PubMed ID: 27735826
[TBL] [Abstract][Full Text] [Related]
6. Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.
Marmé F; Lederer B; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Jackisch C; Kümmel S; Loibl S; Paepke S; Untch M; von Minckwitz G; Schneeweiss A
Eur J Cancer; 2016 Jan; 53():65-74. PubMed ID: 26693900
[TBL] [Abstract][Full Text] [Related]
7. Validation of the CPS+EG and Neo-Bioscore staging systems after preoperative systemic therapy for breast cancer in a single center in China.
Xu L; Duan X; Zhou B; Liu Y; Ye J; Liu Z; Ma C; Zhang H; Zhang S; Zhang L; Zhao J; Cheng Y
Breast; 2018 Aug; 40():29-37. PubMed ID: 29677568
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy.
Soares ICS; Bello MA; Bergmann A; Thuler LCS
Breast Cancer Res Treat; 2021 Jun; 187(2):547-555. PubMed ID: 33417086
[TBL] [Abstract][Full Text] [Related]
9. Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score.
Michel LL; Sommer L; González Silos R; Lorenzo Bermejo J; von Au A; Seitz J; Hennigs A; Smetanay K; Golatta M; Heil J; Schütz F; Sohn C; Schneeweiss A; Marmé F
Breast Cancer Res Treat; 2019 Sep; 177(2):437-446. PubMed ID: 31236813
[TBL] [Abstract][Full Text] [Related]
10. Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer.
Murphy BL; L Hoskin T; Heins CDN; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 Sep; 24(9):2518-2525. PubMed ID: 28484921
[TBL] [Abstract][Full Text] [Related]
11. Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor.
Loibl S; Weber K; Huober J; Krappmann K; Marmé F; Schem C; Engels K; Pfitzner BM; Kümmel S; Furlanetto J; Hartmann A; Darb-Esfahani S; Müller V; Staebler A; von Minckwitz G; Kronenwett R; Denkert C
Clin Cancer Res; 2018 Jul; 24(14):3358-3365. PubMed ID: 29618617
[No Abstract] [Full Text] [Related]
12. Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.
Yang Y; Im SA; Keam B; Lee KH; Kim TY; Suh KJ; Ryu HS; Moon HG; Han SW; Oh DY; Han W; Kim TY; Park IA; Noh DY
BMC Cancer; 2016 Jul; 16():515. PubMed ID: 27444430
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.
Kantor O; Laws A; Pastorello RG; King C; Wong S; Dey T; Schnitt S; King TA; Mittendorf EA
Ann Surg Oncol; 2021 Nov; 28(12):7347-7355. PubMed ID: 33956276
[TBL] [Abstract][Full Text] [Related]
14. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
15. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Marmé F; Solbach C; Michel L; Schneeweiss A; Blohmer JU; Huober J; Fasching PA; Jackisch C; Nekljudova V; Link T; Rhiem K; Rey J; Denkert C; Hanusch C; Tesch H; Lederer B; Loibl S; Untch M
Eur J Cancer; 2021 Aug; 153():203-212. PubMed ID: 34186505
[TBL] [Abstract][Full Text] [Related]
16. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors.
Yi M; Lin H; Bedrosian I; Shen Y; Hunt KK; Chavez-MacGregor M; King TA; Mittendorf EA
Ann Surg Oncol; 2020 Feb; 27(2):359-366. PubMed ID: 31667721
[TBL] [Abstract][Full Text] [Related]
17. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
18. National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.
Puig CA; Hoskin TL; Day CN; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 May; 24(5):1242-1250. PubMed ID: 28000076
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
20. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
